Report Detail
Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Status and Forecast 2019-2025
- RnM3472544 |
- 12 July, 2019 |
- Global |
- 97 Pages |
- QYResearch |
- Other
Inflammatory bowel disease (IBD) is a broad term used to describe disorders involving chronic inflammation of digestive tract. The disease is categorized by severe diarrhea, abdominal pain, fatigue, and weight loss.
Increase in incidences of IBD and rise in adoption of anti-inflammatory drugs drive the market. In addition, strong upcoming pipeline of IBD drugs also boosts the market growth. However, side effects of these drugs over a patients body restrain the market growth. Development of biosimilars for existing drugs, and growth opportunities in the emerging economies of Asia-Pacific and LAMEA provide opportunities for the market growth.
In 2018, the global Inflammatory Bowel Disease (IBD) Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Inflammatory Bowel Disease (IBD) Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Inflammatory Bowel Disease (IBD) Therapeutics development in United States, Europe and China.
The key players covered in this study
Abbvie
Johnson & Johnson
GlaxoSmithKline
Merck
Novartis
Celgene
Pfizer
Salix
Roche
Teva Pharmaceutical
Market segment by Type, the product can be split into
Anti-inflammatory Biologics
Non-Steroidal Anti-inflammatory drugs (NSAIDs)
Corticosteroids
Market segment by Application, split into
Hospital
Research
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Inflammatory Bowel Disease (IBD) Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Inflammatory Bowel Disease (IBD) Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Inflammatory Bowel Disease (IBD) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Anti-inflammatory Biologics
- 1.4.3 Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- 1.4.4 Corticosteroids
- 1.5 Market by Application
- 1.5.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Share by Application (2014-2025)
- 1.5.2 Hospital
- 1.5.3 Research
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Inflammatory Bowel Disease (IBD) Therapeutics Market Size
- 2.2 Inflammatory Bowel Disease (IBD) Therapeutics Growth Trends by Regions
- 2.2.1 Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Regions (2014-2025)
- 2.2.2 Inflammatory Bowel Disease (IBD) Therapeutics Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Manufacturers
- 3.1.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players Head office and Area Served
- 3.3 Key Players Inflammatory Bowel Disease (IBD) Therapeutics Product/Solution/Service
- 3.4 Date of Enter into Inflammatory Bowel Disease (IBD) Therapeutics Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type (2014-2019)
- 4.2 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application (2014-2019)
5 United States
- 5.1 United States Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 5.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in United States
- 5.3 United States Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 5.4 United States Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
6 Europe
- 6.1 Europe Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 6.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in Europe
- 6.3 Europe Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 6.4 Europe Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
7 China
- 7.1 China Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 7.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in China
- 7.3 China Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 7.4 China Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
8 Japan
- 8.1 Japan Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 8.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in Japan
- 8.3 Japan Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 8.4 Japan Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 9.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in Southeast Asia
- 9.3 Southeast Asia Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 9.4 Southeast Asia Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
10 India
- 10.1 India Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 10.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in India
- 10.3 India Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 10.4 India Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
11 Central & South America
- 11.1 Central & South America Inflammatory Bowel Disease (IBD) Therapeutics Market Size (2014-2019)
- 11.2 Inflammatory Bowel Disease (IBD) Therapeutics Key Players in Central & South America
- 11.3 Central & South America Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Type
- 11.4 Central & South America Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Application
12 International Players Profiles
- 12.1 Abbvie
- 12.1.1 Abbvie Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.1.4 Abbvie Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.1.5 Abbvie Recent Development
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.2.4 Johnson & Johnson Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.2.5 Johnson & Johnson Recent Development
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.3.4 GlaxoSmithKline Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.3.5 GlaxoSmithKline Recent Development
- 12.4 Merck
- 12.4.1 Merck Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.4.4 Merck Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.4.5 Merck Recent Development
- 12.5 Novartis
- 12.5.1 Novartis Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.5.4 Novartis Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.5.5 Novartis Recent Development
- 12.6 Celgene
- 12.6.1 Celgene Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.6.4 Celgene Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.6.5 Celgene Recent Development
- 12.7 Pfizer
- 12.7.1 Pfizer Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.7.4 Pfizer Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.7.5 Pfizer Recent Development
- 12.8 Salix
- 12.8.1 Salix Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.8.4 Salix Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.8.5 Salix Recent Development
- 12.9 Roche
- 12.9.1 Roche Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.9.4 Roche Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.9.5 Roche Recent Development
- 12.10 Teva Pharmaceutical
- 12.10.1 Teva Pharmaceutical Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Inflammatory Bowel Disease (IBD) Therapeutics Introduction
- 12.10.4 Teva Pharmaceutical Revenue in Inflammatory Bowel Disease (IBD) Therapeutics Business (2014-2019)
- 12.10.5 Teva Pharmaceutical Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Inflammatory Bowel Disease (IBD) Therapeutics. Industry analysis & Market Report on Inflammatory Bowel Disease (IBD) Therapeutics is a syndicated market report, published as Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Inflammatory Bowel Disease (IBD) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
